Alseres Pharmaceuticals, Inc.
ALSE · OTC
6/30/2014 | 3/31/2014 | 12/31/2013 | 9/30/2013 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.23 | 0.00 | -0.00 | 0.03 |
| FCF Yield | -27.33% | -31.22% | -53.61% | -16.36% |
| EV / EBITDA | -29.53 | -28.03 | 23.66 | -28.70 |
| Quality | ||||
| ROIC | 22.65% | 24.98% | -7.95% | 8.76% |
| Gross Margin | 95.00% | 95.00% | 94.34% | 100.00% |
| Cash Conversion Ratio | 0.85 | 1.16 | -1.61 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.78% | 23.75% | 779,449.38% | 419,218.62% |
| Free Cash Flow Growth | 29.42% | 0.14% | -28.32% | -0.41% |
| Safety | ||||
| Net Debt / EBITDA | -26.39 | -24.30 | 21.64 | -22.49 |
| Interest Coverage | -81.77 | -242.23 | 0.86 | -2.56 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -48,806.94 | -1,899.78 | 0.00 |